Syndax Pharmaceuticals (SNDX) Total Current Liabilities (2015 - 2026)
Syndax Pharmaceuticals (SNDX) posted quarterly Total Current Liabilities of $86.2 million for Q1 2026, down 8.86% year-over-year from $94.6 million in Q1 2025, and down 28.26% quarter-over-quarter from $120.1 million in Q4 2025.
Syndax Pharmaceuticals (SNDX) Total Current Liabilities (2015 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Total Current Liabilities history runs 12 years deep, the most recent figure standing at $86.2 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 8.86% year-over-year to $86.2 million; the TTM figure through Mar 2026 stood at $86.2 million (down 8.86% YoY), while the FY2025 annual figure was $120.1 million, up 16.0% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $86.2 million, down from $120.1 million in the prior quarter.
- The five-year high for Total Current Liabilities was $120.1 million in Q4 2025, with the low at $20.8 million in Q3 2022.
- The 5-year median for Total Current Liabilities is $50.8 million (2024), against an average of $61.6 million.
- The sharpest annual moves came in 2022 and 2025: Total Current Liabilities retreated 27.55% in 2022, then soared 166.03% in 2025.
- Syndax Pharmaceuticals' Total Current Liabilities stood at $29.1 million in 2022, then jumped by 99.88% to $58.1 million in 2023, then jumped by 78.24% to $103.5 million in 2024, then advanced by 16.0% to $120.1 million in 2025, then fell by 28.26% to $86.2 million in 2026.
- Business Quant data shows SNDX's Total Current Liabilities at $86.2 million in Q1 2026, $120.1 million in Q4 2025, and $114.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Syndax Pharmaceuticals | 1.77 Bn | 1.22 Bn | 60.67 Mn | 99.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 99.68 Mn |
| Mar 31, 2026 | 86.17 Mn |
| Dec 31, 2025 | 120.12 Mn |
| Sep 30, 2025 | 114.19 Mn |
| Jun 30, 2025 | 112.99 Mn |
| Mar 31, 2025 | 94.55 Mn |
| Dec 31, 2024 | 103.55 Mn |
| Sep 30, 2024 | 59.38 Mn |
| Jun 30, 2024 | 42.47 Mn |
| Mar 31, 2024 | 50.81 Mn |
| Dec 31, 2023 | 58.10 Mn |
| Sep 30, 2023 | 39.17 Mn |
| Jun 30, 2023 | 30.17 Mn |
| Mar 31, 2023 | 23.72 Mn |
| Dec 31, 2022 | 29.07 Mn |
| Sep 30, 2022 | 20.80 Mn |
| Jun 30, 2022 | 30.93 Mn |
| Mar 31, 2022 | 30.55 Mn |
| Dec 31, 2021 | 20.68 Mn |
| Sep 30, 2021 | 28.71 Mn |